Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUS NASDAQ:EPIX NASDAQ:FIXX NASDAQ:INZY NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsEPIXESSA Pharma$0.19-5.2%$1.36$0.19▼$7.88$9.60M1.618.13 million shs2.12 million shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsINZYInozyme Pharma$4.00$3.99$0.72▼$6.24$258.25M2.27960,267 shsN/ARIGLRigel Pharmaceuticals$37.30-1.7%$30.52$13.37▼$43.72$680.89M1.27730,196 shs742,843 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma-5.22%-18.83%-90.04%-88.62%-97.19%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%INZYInozyme Pharma0.00%0.00%0.00%+0.50%-33.33%RIGLRigel Pharmaceuticals-1.74%-8.74%-5.59%+94.68%+172.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsEPIXESSA Pharma$0.19-5.2%$1.36$0.19▼$7.88$9.60M1.618.13 million shs2.12 million shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsINZYInozyme Pharma$4.00$3.99$0.72▼$6.24$258.25M2.27960,267 shsN/ARIGLRigel Pharmaceuticals$37.30-1.7%$30.52$13.37▼$43.72$680.89M1.27730,196 shs742,843 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma-5.22%-18.83%-90.04%-88.62%-97.19%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%INZYInozyme Pharma0.00%0.00%0.00%+0.50%-33.33%RIGLRigel Pharmaceuticals-1.74%-8.74%-5.59%+94.68%+172.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouos 0.00N/AN/AN/AEPIXESSA Pharma 2.00Hold$2.00940.04% UpsideFIXXHomology Medicines 0.00N/AN/AN/AINZYInozyme Pharma 2.38Hold$11.14178.57% UpsideRIGLRigel Pharmaceuticals 2.40Hold$38.202.41% UpsideCurrent Analyst Ratings BreakdownLatest FIXX, INZY, EPIX, RIGL, and AKUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00INZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ARIGLRigel Pharmaceuticals$267.92M2.50$1.06 per share35.19$0.19 per share196.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AEPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/AFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AINZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%N/ARIGLRigel Pharmaceuticals$17.49M$5.416.8935.52N/A36.51%438.89%57.03%11/6/2025 (Estimated)Latest FIXX, INZY, EPIX, RIGL, and AKUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025EPIXESSA Pharma-$0.17-$0.09+$0.08-$0.09N/AN/A8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69878.84%N/AN/A N/AFIXXHomology MedicinesN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ALatest FIXX, INZY, EPIX, RIGL, and AKUS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30EPIXESSA PharmaN/A69.0669.06FIXXHomology MedicinesN/A7.257.25INZYInozyme Pharma0.652.192.19RIGLRigel Pharmaceuticals0.462.021.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/AEPIXESSA Pharma75.12%FIXXHomology Medicines31.32%INZYInozyme Pharma88.30%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%EPIXESSA Pharma15.50%FIXXHomology Medicines16.10%INZYInozyme Pharma12.18%RIGLRigel Pharmaceuticals9.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableEPIXESSA Pharma5047.31 million39.98 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.32 millionOptionableFIXX, INZY, EPIX, RIGL, and AKUS HeadlinesRecent News About These CompaniesAcadian Asset Management LLC Grows Stock Position in Rigel Pharmaceuticals, Inc. $RIGLSeptember 15 at 4:37 AM | marketbeat.comDynamic Technology Lab Private Ltd Acquires Shares of 27,117 Rigel Pharmaceuticals, Inc. $RIGLSeptember 13 at 3:58 AM | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Down 6.1% - Here's What HappenedSeptember 11, 2025 | marketbeat.comCan Tavalisse Drive Rigel's Growth Through the Rest of 2025?September 11, 2025 | zacks.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Drop in Short InterestSeptember 11, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Grows Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 11, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by AnalystsSeptember 11, 2025 | marketbeat.comWhat Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comA Look At The Intrinsic Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)September 9, 2025 | uk.finance.yahoo.comTrexquant Investment LP Lowers Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 9, 2025 | marketbeat.comDo Options Traders Know Something About RIGL Stock We Don't?September 6, 2025 | msn.comRafferty Asset Management LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGLSeptember 5, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 11,070 Shares of Rigel Pharmaceuticals, Inc. $RIGLSeptember 3, 2025 | marketbeat.comArmistice Capital LLC Has $27.27 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGLSeptember 2, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. $RIGL Shares Bought by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.com115,218 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Nuveen LLCSeptember 1, 2025 | marketbeat.comInvesco Ltd. Purchases Shares of 134,072 Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comVanguard Group Inc. Has $18.50 Million Stake in Rigel Pharmaceuticals, Inc. $RIGLSeptember 1, 2025 | marketbeat.comRigel to Participate in Upcoming September Investor ConferencesAugust 26, 2025 | prnewswire.comThis ‘Darling’ Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out SoonAugust 25, 2025 | finance.yahoo.comThis ‘Darling’ Pharma Stock Is Hitting New HighsAugust 25, 2025 | barchart.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFIXX, INZY, EPIX, RIGL, and AKUS Company DescriptionsAkouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.ESSA Pharma NASDAQ:EPIX$0.19 -0.01 (-5.22%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$0.19 0.00 (-0.68%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Homology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Inozyme Pharma NASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$37.30 -0.66 (-1.74%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$37.48 +0.18 (+0.47%) As of 09/15/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
